ライフサイエンスコーパス: dense breast

1 1 indicates a fatty breast and 4 indicates a dense breast).

2 s of age or women > or =50 years of age with dense breasts).

3 neously dense breasts (24% of all women with dense breasts).

4 tremely dense breasts (21% of all women with dense breasts).

5 r to digital mammography (DM) for women with dense breasts.

6 digital mammography and to the prevalence of dense breasts.

7 mutation carriers who have mammographically dense breasts.

8 breast cancer in women with radiographically dense breasts.

9 om 100% in fatty breasts to 45% in extremely dense breasts.

10 is independently higher in older women with dense breasts.

11 a woman with fatty breasts and a woman with dense breasts.

12 and lower in stage than palpable cancers in dense breasts.

13 n, especially in women with radiographically dense breasts.

14 fibroglandular densities, or heterogeneously dense breasts.

15 omatic FN rates trended higher in women with dense breasts.

16 f breast cancer risk in women with extremely dense breasts.

17 as proved beneficial in women with extremely dense breasts.

18 roup, and in 1/37 (2.7%) cases for extremely dense breasts.

19 ghest rate among women aged 60-70 years with dense breasts.

20 d benign biopsy rate in women with extremely dense breasts.

21 utely most marked among women with extremely dense breasts.

22 of improving cancer detection in women with dense breasts.

23 f patients and 43% in the group of extremely dense breasts.

24 0 years and 46% were performed in women with dense breasts.

25 tal breast tomosynthesis (DBT) in women with dense breasts.

26 st cancer occurrence in women with extremely dense breasts.

27 reening MRI findings in women with extremely dense breasts.

28 screening in female patients with extremely dense breasts.

29 and 2.05 (95% CI: 1.25, 3.36) for extremely dense breasts.

30 ned in 2022, of which 37.5% (6830 women) had dense breasts.

31 SM) can be a viable option for patients with dense breasts.

32 ool, one must be aware of its limitations in dense breasts.

33 if their mammogram was negative and they had dense breasts.

34 l, 36.9% of mammograms were rated as showing dense breasts.

35 a supplemental screening test in women with dense breasts.

36 upplemental screening options for women with dense breasts.

37 hesis and ultrasound in mammography-negative dense breasts.

38 p to 14% in the classification of women with dense breasts.

39 women with mammography-negative screens and dense breasts.

40 t increased risk, particularly in those with dense breasts.

41 ual screening, younger women, and women with dense breasts.

42 en of 14 cancers were detected in women with dense breasts.

43 programs, particularly in younger women with dense breasts.

44 at the patient level after DBT in women with dense breasts.

45 calculated for younger women and those with dense breasts.

46 gital mammography is standard for women with dense breasts.

47 riate in the much larger group of women with dense breasts.

48 r those younger than 50 years and those with dense breasts.

49 densities (P <= .001), except for extremely dense breasts (0.1%, P = .82).ConclusionDigital breast t

50 that 20 of the 45 women had heterogeneously dense breasts, 1 had extremely dense breasts, 20 had pri

51 tly suggested reasons for possible miss were dense breasts (12 of 35; 34%) and distracting lesions (3

52 y, and two were made with supplemental US in dense breasts (2.4 cases per 1000 women).

53 terogeneously dense breasts, 1 had extremely dense breasts, 20 had primarily fatty breasts, and 4 had

54 or greater and heterogeneously or extremely dense breasts (21% of all women with dense breasts).

55 risk of 2.50% or greater and heterogeneously dense breasts (24% of all women with dense breasts).

56 s; interquartile range, 44 to 78 years) with dense breasts, 24 additional BCs were detected (23 invas

57 Of 904 patients, 700 (77.4%) had dense breasts, 247 (27.3%) had a family history of breas

58 ade 2 or 3 among women aged 60-70 years with dense breasts (41 of 7364, 55.4 per 10 000 women; rate d

59 Fewer Black women had extremely dense breasts (561 [2.1%] vs 1464 [5.8%]; P = .02) and g

60 vs. 75.6%; P = 0.071), those with extremely dense breasts (83.6% vs. 68.1%; P = 0.051), and pre- or

61 Conclusion In women with extremely dense breasts, a high volume of enhancing parenchyma on

62 tal ultrasonography screening for women with dense breasts after a negative screening mammography res

63 Using heterogeneously or extremely dense breasts alone would detect more false negatives bu

64 pecificity in female patients with extremely dense breasts, although specificity improved at follow-u

65 Participants with extremely dense breasts (American College of Radiology breast dens

66 Of 132 166 screened patients with dense breast and mammography negative for cancer who met

67 or intermediate risk for breast cancer with dense breast and negative mammogram remains to be determ

68 66%) for 51.0% of women with heterogeneously dense breasts and 52.5% with extremely dense breasts, wi

69 Sensitivity was 68% (162 of 237) for dense breasts and 85% (302 of 356) for nondense breasts

70 study population comprised 37 patients with dense breasts and a family or personal history of breast

71 graphy versus standard of care in women with dense breasts and a negative mammogram.

72 a supplemental screening tool in women with dense breasts and a negative mammogram.

73 o 74 years with heterogeneously or extremely dense breasts and an RR of 4.0.

74 ography for the 3.6% of women with extremely dense breasts and at high risk of breast cancer but not

75 ancer among the 3.6% of women with extremely dense breasts and at high risk of breast cancer.

76 screening outcomes for female patients with dense breasts and different estimated breast cancer risk

77 o 49 years are more likely to have extremely dense breasts and estrogen receptor-negative tumors; if

78 ost markedly reduced with the combination of dense breasts and estrogen replacement therapy use; ther

79 screening MRI scans in women with extremely dense breasts and findings negative for cancer at mammog

80 n In women in the DENSE trial with extremely dense breasts and findings that were negative for cancer

81 Extremely dense breasts and first-degree relatives with breast can

82 r patients with extremely or heterogeneously dense breasts and for patients in their 5th and 7th deca

83 ndular, heterogeneously dense, and extremely dense breasts and for patients younger than 40 years, th

84 t US, and MRI in non-high-risk patients with dense breasts and mammography negative for cancer were r

85 or intermediate risk for breast cancer with dense breasts and mammography negative for cancer.

86 iate risk for breast cancer in patients with dense breasts and mammography with negative findings.

87 ng mammography facilities to tell women with dense breasts and negative results on screening mammogra

88 prospectively examined, all 3,626 women with dense breasts and normal mammographic and physical exami

89 equiring that women be notified if they have dense breasts and that they be advised to discuss supple

90 nsitivity of 2D mammography in patients with dense breasts and the specificity of 2D mammography for

91 ty breasts vs 85.4% for those with primarily dense breasts) and was lower among those with a family h

92 age of 50 years, women with radiographically dense breasts, and premenopausal or perimenopausal women

93 nd for women aged 40 to 49 years, those with dense breasts, and those using combination hormone thera

94 Improved screening methods for women with dense breasts are needed because of their increased risk

95 0.01) and not associated with the change in dense breast area (P = 0.17).

96 er screening with mammography for women with dense breasts, as well as to assess neoadjuvant therapy

97 n than tomosynthesis in mammography-negative dense breasts at a similar FP-recall rate.

98 nopausal women younger than 50 years who had dense breasts at film mammography comprised the only sub

99 m high-grade) with heterogeneously or highly dense breasts at mammography and one papillary low/inter

100 liant retrospective review of 935 women with dense breasts at mammography who subsequently underwent

101 technique is most beneficial for women with dense breasts attending breast screening.

102 o 74 years with heterogeneously or extremely dense breasts averted 0.36 additional breast cancer deat

103 Women with dense breasts benefit from supplemental cancer screening

104 ith a positive FHBC were more likely to have dense breasts (BI-RADS 3-4) compared with women with no

105 ivariable-adjusted model, the odds of having dense breasts (BI-RADS 3-4) were 30% higher (OR, 1.30; 9

106 MRI proved to be slightly more effective in dense breasts, both methods showed similar results in th

107 hallenging in female patients with extremely dense breasts (Breast Imaging Reporting and Data System

108 to earlier detection of cancer in women with dense breasts but does not estimate the level of overdia

109 imenopausal women younger than 50 years with dense breasts, but film tended nonsignificantly to perfo

110 t breast cancer (BC) in mammography-negative dense breasts, but these modalities have not been direct

111 detection of node-negative breast cancer in dense breasts by 7.5 per 1000 women screened (95% CI: 3.

112 er asymmetric densities, except in extremely dense breasts.(C) RSNA, 2019Online supplemental material

113 ered to women in the general population with dense breasts can aid detection of small mammographicall

114 Drug Administration and the benefits of dose-dense breast cancer chemotherapy, especially for hormone

115 ificantly different across the scattered and dense breast categories.

116 ADS a or b (nondense breasts) versus c or d (dense breasts) categories, with an agreement of 90.4% (1

117 In patients with extremely dense breasts, CEM could serve as a complementary or add

118 sult (range, 345 to 421) per 1000 women with dense breasts compared with biennial screening by mammog

119 0.80]; P < .001) and in women with extremely dense breasts compared with those in lower breast densit

120 Odds ratios for women with extremely dense breasts compared with those with scattered areas o

121 e patients with heterogeneously or extremely dense breasts conducted from January 2014 to October 202

122 en at 21 sites with elevated cancer risk and dense breasts consented to 3 annual independent screens

123 for breast cancer screening in patients with dense breast, conventional anatomical ultrasound lacks s

124 aphy screening for only women with extremely dense breasts cost $246,000 per QALY gained (range, $74,

125 th mammography is substantial, especially in dense-breast (DB) women.

126 omatic FN rates trended higher in women with dense breasts (DBT, 0.14 per 1000 screens; DM: 0.07 per

127 with screen-film mammography, in women with dense breasts demonstrated in the DMIST was most likely

128 eening based on heterogeneously or extremely dense breast density and lifetime risk had limited abili

129 sis of breast MRI examinations in women with dense breasts dismissed nearly 40% of MRI scans without

130 ; and women with entirely fatty vs extremely dense breasts (eg, among annual screening in women aged

131 of 2029 [19%]) had the lowest proportion of dense breasts (eight of 390 [2.1%]), whereas similar pro

132 Dense breasts exhibit, on average, significantly higher

133 In women with dense breasts, FFDM plus UST improved cancer detection b

134 Supplemental screening of women with dense breasts finds additional breast cancer but increas

135 Heterogeneously or extremely dense breasts, first-degree family history of breast can

136 total of 4581 MRI examinations of extremely dense breasts from 4581women (mean age, 54.3 years; inte

137 alone among U.S. women aged 50-74 years with dense breasts from a federal payer perspective and a lif

138 In contrast, interval breast cancers in dense breasts (> 40.9% mammographic density) were less a

139 The group of women with dense breasts had a higher RR (5.5% vs. 2.8%) (P-value <

140 Dense breasts had an average SUVmax of 1.243 and mean SU

141 easts had low scattering power and extremely dense breasts had higher values.

142 The remaining 475 asymptomatic women with dense breasts had negative/benign DBT examinations befor

143 Debate on adjunct screening in women with dense breasts has followed legislation requiring that wo

144 Women with dense breasts have an increased lifetime risk of maligna

145 Women with extremely dense breasts have an increased risk of breast cancer an

146 Women with dense breasts have elevated risk of false-negative mammo

147 ging is justified because not all women with dense breasts have high interval cancer rates.

148 1.19 to 4.46) or heterogeneous or extremely dense breasts (HR, 2.61; 95% CI, 1.44 to 4.72), with no

149 ity and rates of screening mammography among dense (Breast Imaging Reporting and Data System [BI-RADS

150 aphy in a generalizable cohort of women with dense breasts increased the cancer detection yield of cl

151 ltrasound in Women With Mammography-Negative Dense Breasts' interim analysis shows that ultrasound ha

152 ltrasound in Women With Mammography-Negative Dense Breasts is a prospective multicenter study recruit

153 reening for U.S. women aged 50-74 years with dense breasts is likely to be cost-effective if priced a

154 n selected populations, including women with dense breasts, mammographically indeterminate lesions >1

155 hose with heterogeneously dense or extremely dense breasts (n = 427), normal or benign ultrasounds.

156 rogeneously dense breasts, or with extremely dense breasts not at high risk.

157 t laws requiring notifications to women with dense breasts of their increased BC risk.

158 onography or MRI in women identified to have dense breasts on an otherwise negative screening mammogr

159 or other methods in women identified to have dense breasts on an otherwise negative screening mammogr

160 omen with heterogeneously dense or extremely dense breasts on mammography (difference, 0.11; 95 perce

161 Extremely dense breasts on mammography or first-degree relatives w

162 = 1007) who had heterogeneously or extremely dense breasts on prior mammograms and additional risk fa

163 -year risk of 1.67% or greater and extremely dense breasts or 5-year risk of 2.50% or greater and het

164 in the prior 2 years and had heard the term dense breasts or breast density.

165 01) but no difference in the percentage with dense breasts or in the percentage with availability of

166 insurance coverage for women with extremely dense breasts or those with heterogeneously dense breast

167 CI: 2.4, 5.1]), and patients with extremely dense breasts (OR = 2.8 [95% CI: 1.3, 5.8]) compared wit

168 nge, 0.68-0.76; P < .001) than in those with dense breasts (OR range, 0.86-0.90; P <= .05; P interact

169 women with nondense breasts, heterogeneously dense breasts, or with extremely dense breasts not at hi

170 In the women with dense breasts, overall cancer detection increased by 17%

171 nificantly higher than that of patients with dense breasts (P < 0.01).

172 y lower for primarily fatty breasts than for dense breasts (P < 0.01).

173 e densest breasts) and in younger women with dense breasts (P =.02); the effects were independent.

174 ning deficiencies for fatty breasts than for dense breasts (P =.028).

175 for breast cancer was higher for women with dense breasts (P-value = .013).

176 malignancy in 18 of 20 (90%) cancers despite dense breast parenchymal patterns (BI-RADS types 3 and 4

177 asymptomatic female patients with extremely dense breasts performed from December 2012 to March 2022

178 dense breasts or those with heterogeneously dense breasts plus a greater than 20% lifetime breast ca

179 h Volpara classifying 51% of women as having dense breasts, Quantra classifying 37%, and clinical BI-

180 ized mammography than digital mammography in dense breasts, relatively and absolutely most marked amo

181 sitivities of 0.88 and 0.78 for nondense and dense breasts, respectively, RRonset was 1.73 (95% CI, 1

182 all women with heterogeneously or extremely dense breasts shifted to scattered fibroglandular breast

183 creenings), and 2.3 in category D (extremely dense breasts) (six of 2629 screenings).

184 Women with dense breasts subsequently underwent screening US.

185 s--were significantly greater for women with dense breasts than for women with nondense breasts, even

186 In dense breasts, the average SUV was 0.39 +/- 0.05 (right

187 In the group of patients with extremely dense breasts, the sensitivity of the method was 97.3%,

188 Dense breasts; the law mandates insurance coverage for w

189 re common in mammograms with heterogeneously dense breast tissue (8% unacceptable) than in those with

190 among the 156 women who had radiographically dense breast tissue (Breast Imaging Reporting and Data S

191 percentage of mammograms reported as showing dense breast tissue (hereafter called "dense mammograms"

192 r disagreement by 1.56% in women with highly dense breast tissue (P < .0001).

193 examination for the subset of women who have dense breast tissue and are at high risk of breast cance

194 mental MRI screening in women with extremely dense breast tissue and normal results on mammography re

195 n the ages of 50 and 75 years with extremely dense breast tissue and normal results on screening mamm

196 cent mammographic density, the proportion of dense breast tissue area to total breast area, declines

197 ature were used to recommend that women with dense breast tissue at screening mammography follow supp

198 r for the most dense compared with the least dense breast tissue categories ranges from 1.8 to 6.0, w

199 Dense breast tissue contains more stromal collagen, whic

200 tandard of care for breast cancer screening, dense breast tissue decreases mammographic sensitivity.

201 Patients with mammographically dense breast tissue have a greatly increased risk of dev

202 6, 2809 women, with at least heterogeneously dense breast tissue in at least 1 quadrant, were recruit

203 Extremely dense breast tissue is a risk factor for breast cancer a

204 Mammographically dense breast tissue is one of the greatest risk factors

205 ften develop the disease at a young age when dense breast tissue reduces the sensitivity of X-ray mam

206 of women with heterogeneously and extremely dense breast tissue, a working group of breast imagers a

207 of BRCA1 and BRCA2 mutations tended to have dense breast tissue, and their mammographic patterns ten

208 ancer detection, especially in patients with dense breast tissue, but its utility is limited by low d

209 n particular, issues of risk associated with dense breast tissue, masking of cancers by dense tissue

210 ography is limited, especially in women with dense breast tissue.

211 screening arises from the masking effect of dense breast tissue.

212 ty ranged from 62.9% in women with extremely dense breasts to 87.0% in women with almost entirely fat

213 increased from 89.1% in women with extremely dense breasts to 96.9% in women with almost entirely fat

214 An RCT randomizing individuals with dense breasts to invitations for supplemental screening

215 compromised sensitivity in radiographically dense breasts, ultrasonography lacks specificity and has

216 ears with heterogeneously dense or extremely dense breasts undergoing routine screening.

217 Among women with dense breasts undergoing screening, abbreviated breast M

218 The likelihood of a woman being told she has dense breasts varies substantially according to which ra

219 breast US screening outcomes for women with dense breasts vary with levels of breast cancer risk.

220 ncer associations; odds ratios for extremely dense breasts versus scattered fibroglandular densities

221 formed had DB, and 55 (26.6%) cases had very dense breasts (very DBs).

222 normal screening mammography with extremely dense breasts (Volpara density category 4) were prospect

223 However, the highest peak SUV observed in dense breasts was 1.39, which is well below the SUV of 2

224 8%; 95% CI, 31.7%-47.3%) whose prevalence of dense breasts was high (62%-79%).

225 One-year AUCs for nondense versus dense breasts were 0.72 versus 0.58 (P = .10).

226 tives with breast cancer, or heterogeneously dense breasts were associated with a 1.5- to 2.0-fold in

227 In contrast, dense breasts were associated with a lower incidence of

228 eterogeneously (50%-75%) or extremely (>75%) dense breasts were included, regardless of further risk

229 n age, 55.7 years +/- 6 [SD]) with extremely dense breasts were included; of these women, 122 (3%) we

230 Extremely dense breasts were present in 86 (10.9%) patients.

231 ulticenter trial from five sites, women with dense breasts were prospectively enrolled from 2017 to 2

232 Higher proportions of failures in dense breasts were related to compression (P <.001) and

233 erties for scintimammography of fatty versus dense breasts were, respectively, sensitivity, 72% versu

234 ound that ER-positive tumours were common in dense breasts, which was statistically significant.

235 : 66, 87) from nine studies in patients with dense breasts, while in 10 studies on mammography-detect

236 f 1 for screening of asymptomatic women with dense breasts who are 40 years old and older, it does no

237 tireader multicase study included women with dense breasts who underwent FFDM and UST at 10 centers b

238 one, and mammography plus BSGI in women with dense breasts who were asymptomatic and examined in the

239 er sensitivity and specificity in women with dense breasts, who experience higher breast cancer risk.

240 y, 122 patients (including 108 patients with dense breasts) with ambiguous FFDM findings were imaged

241 ously dense breasts and 52.5% with extremely dense breasts, with interval cancer rates of 0.58 to 0.6

242 tal ultrasonography screening for women with dense breasts would substantially increase costs while p